

**(19) World Intellectual Property
Organization
International Bureau**



(43) International Publication Date
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number
WO 2005/010213 A3

(51) International Patent Classification⁷: C12Q 1/68

Taieri, Dunedin (NZ). HOLYOAKE, Andrew, John
[NZ/NZ]; 41 Rychill Street, Dunedin (NZ).

(21) International Application Number:
PCT/US2004/022959

(74) Agents: BORSON, D., Benjamin et al.; FLIESLER MEYER LLP, Four Embarcadero Center, Fourth Floor, San Francisco, California 94111-4156 (US).

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language: English

(26) **Publication Language:** English

(30) Priority Data:
60/487,906 17 July 2003 (17.07.2003) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AF, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (for all designated States except US): PAFIC EDGE BIOTECHNOLOGY, LTD. [NZ/NZ]; Centre for Innovation, 87 St. David Street, Dunedin (NZ). FARMER, Charles, Davis, Jr. [US/US]; 97 Giles Road, East Kingston, NH 03827 (US).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** GUILFORD, Parry, John [NZ/NZ]; 38 Riccarton Road East, East

[Continued on next page]

(54) Title: MARKERS FOR DETECTION OF GASTRIC CANCER



(S7) Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and/or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.

WO 2005/010213 A3

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
15 September 2005